GlassScriptPhysician profile
Christopher W Sturbaum
NPI 1457361560
$29,905.22
in general payments reported to CMS, 2019-2025
28 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $250 · 2021: $325 · 2022: $11K · 2023: $4,979 · 2024: $1,532 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,841 · Food and Beverage: $2,211 · Consulting Fee: $990 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,841.40 |
| Food and Beverage | $2,210.51 |
| Consulting Fee | $990.13 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $18,269.71 | 2019-2024 | Healon Duet Pro, Tecnis Simplicity, Veritas Vision System |
| Biotissue Holdings INC. | $5,368.48 | 2022-2024 | |
| Allergan, INC. | $2,686.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $530.65 | 2019-2022 | |
| Abbvie INC. | $512.30 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Sun Pharmaceutical Industries INC. | $377.35 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Rxsight INC | $320.57 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Mallinckrodt Enterprises LLC | $242.75 | 2019 | |
| Mallinckrodt Hospital Products INC. | $242.15 | 2021-2025 | Acthar |
| Alcon Vision LLC | $185.07 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Dompe US, INC. | $166.43 | 2019-2025 | Oxervate |
| Glaukos Corporation | $157.28 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $154.80 | 2023-2025 | Tyrvaya, Ryzumvi |
| Merz Pharmaceuticals, LLC | $147.69 | 2021-2025 | Xeomin |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.28 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $60.37 | 2024 | Xdemvy |
| Harrow Eye, LLC | $58.22 | 2023-2025 | Vevye, Tobradex St, Natacyn |
| Aerie Pharmaceuticals, INC. | $40.45 | 2019-2021 | |
| Lumibird Medical INC. | $40.10 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.82 | 2019-2023 | Eylea |
| Astellas Pharma US INC | $34.44 | 2024 | Izervay |
| Rayner Intraocular Lenses Limited | $33.35 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Shire North American Group INC | $32.65 | 2019 | |
| Omeros Corporation | $29.88 | 2021 | |
| Bausch & Lomb Americas INC. | $24.82 | 2024 | Miebo |
| Carl Zeiss Meditec USA, INC. | $23.65 | 2022 | |
| Horizon Therapeutics Plc | $15.93 | 2023 | Tepezza |
| Ivantis, INC | $15.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sturbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.